Revisiting the role of FVIII in Haemophilia A in 2026
About this episode
This episode explores the evolving role of Factor VIII in the management of haemophilia A in 2026 with expert insights.
In this episode, Cedric Hermans sits down with Jan Blatný, Consultant Haematologist at Masaryk University and University Hospital Brno, EHCC and EuroBloodNet Centre, and former EAHAD President (2024–2026), to explore the evolving role of Factor VIII in the management of haemophilia A in 2026. As new therapies such as emicizumab, rebalancing agents, and gene therapy reshape the treatment landscape, this conversation revisits where FVIII remains essential.
More episodes of EAHAD
- Meet the Author Ep. 10: The effects of traumatic pain memories on current pain experience in men with haemophilia
- E-Learning Ep. 14: Heavy Menstrual Bleeding in Women with Very Rare Coagulation Factor Deficiencies
- Meet the Author Ep. 9: The Developing Role of Occupational Therapy within Haemophilia Services
- Meet the Author Ep. 8: A single centre experience with clinical use of Neria™ Guard as mode of pain and distress management in the administration of emicizumab in children
- Meet the Author Ep.7: Acute neuromuscular and perceptual responses to blood flow restriction exercise in adults with severe haemophilia: a pilot study
- Meet the Author Ep. 6: Exercise-based telerehabilitation for the management of chronic pain in people with severe haemophilia: a mixed-methods feasibility study
Explore listener stats, chart rankings, contacts and more on the EAHAD podcast page.